(Press-News.org) Hypertriglyceridemia, or high levels of lipids (fats) in the blood, increases the risk of heart attack, stroke and acute pancreatitis. Currently available medications, including statins, ezetimibe, fibrates and prescription omega 3 fatty acids, typically lower triglyceride levels by anywhere from below 10% to up to 40%. These therapies help, but they are not enough to prevent cardiovascular events in everyone.
An experimental treatment could further lower triglycerides in the blood, according to a placebo-controlled and double-blind trial led by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system. Results were presented at the 2024 American College of Cardiology’s Annual Scientific Session & Expo and simultaneously published in the New England Journal of Medicine.
The trial randomized 154 adults on lipid-lowering therapy with moderate or severe hypertriglyceridemia to receive either 50mg olezarsen, 80mg olezarsen or placebo. Olezarsen is an antisense oligonucleotide that inhibits APOC3, a gene associated with higher levels of triglycerides, by targeting its mRNA. The subcutaneous medication was administered every four weeks, for a period of a year.
Olezarsen reduced triglyceride levels by 49% at the 50mg dose and 53% at the 80mg dose, compared with placebo. The experimental drug also reduced apolipoprotein B and non-HDL cholesterol, which are important in plaque formation, by 18 to 18.5% and 23% to 25%, respectively.
While larger and longer-term studies are needed to further assess the efficacy and safety of olezarsen in preventing heart attacks and strokes, the research opens up new avenues for improving the health of people with high cardiovascular risk. “These findings indicate that targeting APOC3 mRNA is a promising new pathway for lowering triglycerides and potentially reducing the risk of heart attack and stroke,” said corresponding author Brian Bergmark, MD, of the Division of Cardiovascular Medicine at Brigham and Women’s Hospital.
END
Experimental drug could further reduce lipids in the blood in high-risk patients
2024-04-07
ELSE PRESS RELEASES FROM THIS DATE:
New evidence links passive smoking with dangerous heart rhythm disorder
2024-04-07
Berlin, Germany – 7 April 2024: Exposure to secondhand smoke – even at small amounts – is linked with greater risk of a serious heart rhythm disorder, according to research presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).1 The likelihood of atrial fibrillation increased as the duration of passive smoking lengthened.
“The dangers of secondhand smoke were significant regardless of whether individuals were at home, outdoors, or at work, indicating that exposure universally elevates the risk of atrial ...
Oral vaccine for UTI is potential alternative to antibiotics, finds 9-year study
2024-04-07
Recurrent Urinary Tract Infections (UTIs) can be prevented for up to nine years in more than half of people given an oral spray-based vaccine and is a potential alternative to antibiotic treatments, finds research.
Initial results from the first long-term follow-up study of the safety and effectiveness of the MV140 vaccine for recurrent UTIs are presented this weekend at the European Association of Urology (EAU) Congress in Paris.
They show that in both men and women with recurrent UTIs, 54% of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported. Full results of the study are expected to be published ...
Antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures
2024-04-06
About The Study: This systematic review and meta-analysis including data on 1.1 million cases of infective endocarditis found that antibiotic prophylaxis was associated with a reduced risk of infective endocarditis following invasive dental procedures in individuals at high risk but not in those at moderate or low/unknown risk. Currently, there is insufficient data to support any benefit of antibiotic prophylaxis in individuals at moderate risk.
Authors: Federica Turati, Ph.D., of the ...
A multimodal video-based AI biomarker for aortic stenosis development and progression
2024-04-06
About The Study: In this cohort study of patients without severe aortic stenosis undergoing echocardiography or cardiac magnetic resonance imaging, a new artificial intelligence (AI)-based video biomarker was independently associated with aortic stenosis development and progression, enabling opportunistic risk stratification across cardiovascular imaging modalities as well as potential application on handheld devices.
Authors: Rohan Khera, M.D., M.S., of the Yale School of Medicine in New Haven, Connecticut, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.0595)
Editor’s ...
Inter-atrial shunts may benefit some heart failure patients while harming others
2024-04-06
Inter-atrial shunts—investigational devices that create a small pathway for blood to pass from the left to the right side of the heart in order to improve heart failure symptoms and outcomes—may be beneficial to heart failure patients with reduced left ventricular ejection fraction (LVEF) but harmful or even deadly for heart failure patients with preserved LVEF, a new Mount Sinai-led study shows.
The findings of the RELIEVE-HF trial were announced during the opening late-breaking trial session at the American College of Cardiology Scientific Sessions on Saturday, April 6. This is the first study ...
Prostate cancer screening with PSA, Kallikrein Panel, and MRI
2024-04-06
About The Study: In this preliminary descriptive report from an ongoing randomized clinical trial, one additional high-grade cancer per 196 men and one low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to undergo screening. These preliminary findings from a single round of screening should be interpreted cautiously, pending results of the study’s primary mortality outcome.
Authors: Anssi ...
PSA screening and 15-year prostate cancer mortality
2024-04-06
About The Study: A single invitation for prostate-specific antigen (PSA) screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years in this secondary analysis of a randomized clinical trial. However, the absolute reduction in deaths was small.
Authors: Richard M. Martin, B.M., B.S., Ph.D., of the University of Bristol in Bristol, United Kingdom, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.4011)
Editor’s ...
Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis
2024-04-06
The largest study to date investigating a single invitation to a PSA blood test* to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers.
The CAP trial, published in the Journal of the American Medical Association (JAMA) and carried out by researchers from the universities of Bristol, Oxford and Cambridge, involved over 400,000 men aged 50-69. Just under half received a single invitation for a PSA test as part of the trial.
After following up for 15 years, there was a small difference in the number of men who died from prostate cancer between the ...
Five-year interval is safe for prostate cancer screening, research shows
2024-04-06
A simple blood test every five years is sufficient to screen low risk men for prostate cancer, new research has shown.
The PSA blood test checks the level of prostate-specific antigen, a marker for prostate cancer. In Europe, only Lithuania routinely screens men for prostate cancer based on their PSA levels, as the test has historically been seen as insufficiently reliable.
The German study, presented at the European Association of Urology (EAU) Congress in Paris today [April 6, 2024], involved over 12,500 men aged between 45-50 taking part in the ongoing ...
Urine test halves painful procedures in bladder cancer follow up, new trial shows
2024-04-06
A simple urine test can more than halve the number of cystoscopies necessary to follow up high-risk bladder cancer patients, new research has found.
Cystoscopies involve inserting a flexible probe through the urethra into the bladder, which allows a clinician to look at the bladder lining for signs of cancer. While they are predominantly safe procedures, cystoscopies do incur some risk of urinary infections and bleeding. They can also cause pain and discomfort.
Initial results from a two-year study, presented today ...